Production (Stage)
Ondine Biomedical Inc.
OBIMF
$0.14
$0.00392.87%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -30.31% | 0.03% | 24.64% | 26.09% | 28.11% |
| Total Depreciation and Amortization | -5.15% | -2.23% | 0.00% | 7.55% | 14.81% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 135.84% | 15.79% | -58.34% | -58.57% | -59.32% |
| Change in Net Operating Assets | 722.62% | 784.75% | 1,118.38% | 4,609.52% | -590.95% |
| Cash from Operations | -11.66% | 6.56% | 22.99% | 20.84% | 19.54% |
| Capital Expenditure | 94.36% | 94.17% | 94.03% | 64.88% | 46.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 94.36% | 94.17% | 94.03% | 64.88% | 46.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -125.76% | -86.70% | -35.38% | -50.26% | -69.44% |
| Issuance of Common Stock | 367.83% | 591.18% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -175.86% | -354.43% | -- | -8,378.26% | -2,943.48% |
| Cash from Financing | 463.90% | 782.26% | 2,927.95% | 2,233.91% | 1,419.07% |
| Foreign Exchange rate Adjustments | 705.15% | 166.05% | -76.29% | -101.58% | -126.65% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 165.08% | 113.29% | 80.54% | 60.21% | 41.22% |